-

QurAlis Invited to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has been invited to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 8:30AM PT at the Westin St. Francis in Elizabethan Room D.

The QurAlis corporate presentation can be accessed by visiting the presentations section of the Company’s website at www.quralis.com.

About QurAlis Corporation

At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.

Contacts

Kathy Vincent
kathy.vincent@quralis.com
310-403-8951

QurAlis Corporation


Release Versions

Contacts

Kathy Vincent
kathy.vincent@quralis.com
310-403-8951

More News From QurAlis Corporation

QurAlis Receives FDA Clearance for IND Application of QRL-201 for the Treatment of ALS, Clearing a Path to Initiation of Pivotal Clinical Trial in the U.S.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation (“QurAlis”), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QRL-201 for the treatment of amyotrophic lateral sclerosis (ALS). The clearance enables QurAlis to advance the planned pivotal CONQUR clinical trial in the U.S. The company also announced final data from the dose-range finding (DRF) phase of its Proof-of-Concept Phase 1/2 ANQUR clinical trial of QRL-20...

QurAlis to Participate in Upcoming Investor Conferences in September

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will participate at the following investor conferences in September. Management will also participate in one-on-one investor meetings. Wells Fargo Securities 21st Annual Healthcare...

QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced interim data from its Proof-of-Concept Phase 1/2 ANQUR clinical trial of QRL-201 in people living with amyotrophic lateral sclerosis (ALS). Results from this study demonstrated QRL-201 had an effect on disease pro...
Back to Newsroom